Authors

Grace Collord, University of Cambridge
Patrick Tarpey, Wellcome Sanger Institute
Natalja Kurbatova, Wellcome Trust
Inigo Martincorena, Wellcome Sanger Institute
Sebastian Moran, Bellvitge Biomedical Research Institute
Manuel Castro, Bellvitge Biomedical Research Institute
Tibor Nagy, Wellcome Sanger Institute
Graham Bignell, Wellcome Sanger Institute
Francesco Maura, IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
MD Young
Jorge Berna, University of Santiago de Compostela
Jose M.C. Tubio, University of Santiago de Compostela
Chris E. McMurran, Cambridge University Hospitals NHS Foundation Trust
AMH Young
Mathijs Sanders, Erasmus University Rotterdam
Imran Noorani, Cambridge University Hospitals NHS Foundation Trust
Stephen J. Price, Cambridge University Hospitals NHS Foundation Trust
Colin Watts, University of Birmingham
Elke Leipnitz, Technische Universität Dresden
Matthias Kirsch, Technische Universität Dresden
Gabriele Schackert, Technische Universität Dresden
Danita Pearson, Cambridge University Hospitals NHS Foundation Trust
Abel Devadass, Cambridge University Hospitals NHS Foundation Trust
Zvi Ram, Tel Aviv Sourasky Medical Center
V. Peter Collins, Cambridge University Hospitals NHS Foundation Trust
Kieren Allinson, Cambridge University Hospitals NHS Foundation Trust
Michael D. Jenkinson, The Walton Centre NHS Foundation Trust
Rasheed Zakaria, The Walton Centre NHS Foundation Trust
Khaja Syed, The Walton Centre NHS Foundation Trust
C. Oliver Hanemann, Peninsula Medical School
Jemma Dunn
MW McDermott
Ramez W. Kirollos
George S. Vassiliou
Manel Esteller
Sam Behjati
Alvis Brazma
Thomas Santarius
U McDermott

ORCID

Abstract

Anaplastic meningioma is a rare and aggressive brain tumor characterised by intractable recurrences and dismal outcomes. Here, we present an integrated analysis of the whole genome, transcriptome and methylation profiles of primary and recurrent anaplastic meningioma. A key finding was the delineation of distinct molecular subgroups that were associated with diametrically opposed survival outcomes. Relative to lower grade meningiomas, anaplastic tumors harbored frequent driver mutations in SWI/SNF complex genes, which were confined to the poor prognosis subgroup. Aggressive disease was further characterised by transcriptional evidence of increased PRC2 activity, stemness and epithelial-to-mesenchymal transition. Our analyses discern biologically distinct variants of anaplastic meningioma with prognostic and therapeutic significance.

DOI

10.1038/s41598-018-31659-0

Publication Date

2018-09-10

Publication Title

Scientific Reports

Volume

8

Issue

1

ISSN

2045-2322

Embargo Period

2018-09-21

First Page

13537

Last Page

13537

Share

COinS